John is a tumour immunologist with extensive experience of developing lab on a chip technology for analysing tumour biopsies.
He has published over 150 peer-reviewed publications and his immunobiology group works closely with clinicians, chemists and engineers.
The majority of his research work has focused on tumours of the head and neck region, identifying novel markers of progression or treatment response.
Coming from an immunology background, Professor Greenman is extremely interested in understanding how the immune system is often subverted during carcinogenesis, and more importantly how such knowledge can be used clinically (diagnostically, prognostically or therapeutically).
1991–1995 Post-doctoral Research Fellow, Sir William Dunn School of Pathology, MRC Cellular Immunology Unit, University of Oxford
1995-1999 Lecturer in Immunology, Dept of Surgery, University of Hull
1999-2004 Senior Lecturer in Tumour Immunology, University of Hull
2004- 2009 Reader in Tumour Immunology, University of Hull
Currently a member of the NC3Rs David Sainsbury Fellowship Panel 2015 -
REF2014 - Appointed as Output Assessor for Panel UoA3 (2014)
Title: Patient tissue on chip – a personalized medicine option?
Over the past decades there have been many advances in making 3D structures that mimic the in vivo situation. As an alternative the biomicrofluidic group at the University of Hull have been characterizing and optimizing devices that can maintain fresh tissue biopsies, mainly from solid tumours, in a functional state. The challenges with fresh tissue are ensuring effective nutrients and removal of waste products over a sufficiently long period to allow investigation. A range of devices have been fabricated and tested in glass and a range of polymers, studying various human tissues including: squamous cell carcinoma of the head & neck, ovarian and colorectal carcinoma, normal liver and heart. These samples have been subjected to different chemotherapy and chemoradiotherapy protocols and the effects measured through analysis of the supernatant or post-treatment tissue. A summary of current data will be given highlighting future potential and limitations of this approach both clinically and as a technology platform.